CytomX upgraded to Neutral at J.P. Morgan

on MSN ago, source:

Stock via Getty Images CytomX Therapeutics (NASDAQ:CTMX) has been upgraded to Neutral from Underweight by J.P Morgan Research ...

CytomX Therapeutics, Inc. (CTMX)

6d ago, source: Yahoo Finance

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the ...

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

21d ago, source: Business Insider

April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript

1mon ago, source: Yahoo Finance

CytomX Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by.

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

1mon ago, source: Nasdaq

The company has a four-quarter earnings surprise of 45.44%, on average. CytomX Therapeutics, Inc. Price and EPS Surprise CytomX Therapeutics, Inc. price-eps-surprise | CytomX Therapeutics ...

CytomX Therapeutics Inc CTMX

2d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

21d ago, source: Stockhouse

April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with ...

CytomX Therapeutics Inc CTMX

20d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CytomX Therapeutics Inc.

27d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

CytomX Therapeutics Inc (CTMX)

20d ago, source: Investing

CytomX Therapeutics (NASDAQ:CTMX) reported Q2 EPS of ($0.37), in-line with the analyst estimate of ($0.37). Revenue for the quarter came in at $18.17 million versus the consensus ...